• 대한방사선치료학회지
• /
• 제25권2호
• /
• pp.115-121
• /
• 2013

목 적: 최신 선형가속기와 새로운 평가 장비를 도입하게 되어 이를 임상에 적용하기 위한 준비과정 중 몇 가지 문제가 발생하여 유용성을 확인하는 과정을 분석함으로써 앞으로 이 장비를 도입하는 기관에 도움이 되고자 한다. 대상 및 방법: 모든 측정은 TrueBEAM STX (Varian, USA)를 이용하였으며, 전산화치료계획장비(Eclipse ver 10.0.39, Varian, USA)를 이용하여 각 에너지 별, 조사조건 별 선량분포파일을 산출하였다. MapCHECK 2의 고유의 성능과 오차로 발생 할 수 있는 원인에 대하여 측정 및 분석하였다. MapCHECK 2의 성능 확인을 위해 6X, 6X-FFF (Flattening Filter Free), 10X, 10X-FFF, 15X의 에너지별로 필드사이즈 $10{\times}10$ cm, gantry $0^{\circ}$, $180^{\circ}$ 방향에서 측정을 하였다. 또한 기존 IGRT couch의 CT값이 volumetric dosimetry에 영향을 주는지 확인을 위해서, CT 넘버 값: -800 (Carbon) & -950 (COUCH안의 공기), -100 & -950을 지정해준 상태에서 6X-FFF, 15X의 에너지별로 필드사이즈 $10{\times}10$ cm, gantry $0^{\circ}$, $180^{\circ}$, $135^{\circ}$, $275^{\circ}$ 방향에서 측정을 하였고, MapPHAN에 할당된 HU 값 확인을 위해 Solid water phantom 3 cm을 위로 얹은 MapCHECK 2와 치료계획용 컴퓨터를 이용해 비교하였고, MapPHAN의 각진 모서리에 의한 측정오류문제, MapPHAN의 gantry 방향 의존성을 알아보기 위해 3가지 방법으로 측정 하였다. 세로로 세운 세팅 상태에서 6X-FFF, 15X를 GANTRY $90^{\circ}$, $270^{\circ}$ 방향에서 각각 측정하고, 가로로 세운 세팅상태에서 에너지 6X-FFF, 15X를 필드사이즈 $10{\times}10$ cm, $90^{\circ}$, $45^{\circ}$, $315^{\circ}$, $270^{\circ}$의 방향에서 각각 측정하였다. 세 번째로 빔의 세기조절을 하지 않은 상태에서 open arc를 조사하였다. 결 과: MapCHECK의 기본 성능을 확인, Couch에 의한 감약 측정, MAP-PHAN에 할당하는 HU값 측정, MapPHAN의 각진 모서리에 대한 계산 정확도 확인을 위한 측정에서 모두 유효한 범위에 들어와 측정오류에 영향을 미치지 않는 것을 확인 할 수 있었다. Gantry 방향의존성 확인하기 위한 3가지 방법 중 첫 번째로 측정기를 세운 상태에서의 값은 Gantry $270^{\circ}$ (상대적 $0^{\circ}$), $90^{\circ}$ (상대적 $180^{\circ}$)에서 6X-FFF, 15X에서 각각 -1.51, 0.83%와 -0.63, -0.22%를 나타내어 AP/PA 방향에 의한 영향이 없음을 나타냈다. 측정기를 가로로 세팅한 상태에서는 Gantry $90^{\circ}$, $270^{\circ}$에서 에너지 6X-FFF 4.37, 2.84%, 15X에서는 -9.63, -13.32%의 차이가 측정되어 gamma pass rate 3%의 값보다 큰 값을 나타내므로 MapPHAN에 의한 측방향 측정값이 유효범위 안에 들지 못하는 것을 확인 할 수 있었다. 마지막 Open Arc에서 6X-FFF, 15X 에너지를 필드사이즈 $10{\times}10$ cm에 $360^{\circ}$ 회전상태에서의 선량분포를 보면 pass rate가 90% 가까이 나오는 것을 확인 할 수 있다. 결 론: 위 결과를 토대로 MapPHAN은 상대등선량분포 감마값 측정에는 적합 하지만, 측방향 빔에 대한 gantry 방향의 의존성 때문에 절대선량은 정확한 측정을 할 수 없는 것으로 판단되어진다. 본 논문에서는 더욱 정확한 치료계획 확인을 위해서 VMAT 같은 회전조사시 측방향에 대한 오차를 줄이고 정확한 절대선량을 측정하기 위해서 MapCHEK 2와 IMF (Isocentric Mounting Fixture)의 조합을 사용하여 gantry 방향 의존성에 의한 영향을 최소화 할 수 있을 것이라 판단된다.

• 대한본초학회지
• /
• 제21권1호
• /
• pp.33-42
• /
• 2006

Objectives : The purpose of this study was to investigate the anticancer effects of Bodusan (BDS) on SNU-1 cells, a human gastric cancer cell line. Methods : To study the cytotoxic effect of BDS on SNU-1 cells, the cells were treated with various concentrations of BDS and then cell viability was determined by XTT reduction method and trypan blue exclusion assay. The typical signs of apoptosis, was examined by western blot analysis. BDS-induced MAPK activation was also examined by Western blot for phosphorylated ERK and p38. Results : BDS reduced proliferation of SNU-1 cells in a dose-dependent manner and decreased procaspase 3 level in a dose-dependent manner and induced the clevage of PARP at concentration > 500 ${\mu}g/ml$. BDS also triggered the mitochondrial apoptotic signaling by increasing the release of cytochrome C from mitochondria to cytosol and reducing the level of anti-apoptotic Bcl-2. BDS significantly decreased ERK phosphorylation and increased p38 phosphorylation in a dose-dependent manner. Futhermore, BDS treatment up-regulated p53 and p21waf expression in a dose-dependent manner. Conclusion : BDS-induced apoptosis is MAP kinase-dependent apoptoric pathway and arrested SNU-1 cells at the G0/G1 of cell cycle. These results suggest that BDS is potentially useful as a chemotherapeutic agent in human gastric cancer.

• Journal of Radiation Protection and Research
• /
• 제42권1호
• /
• pp.9-15
• /
• 2017

Background: The purpose of this study is to assign an appropriate density to virtual phantom for 2D diode array detector with different dose calculation algorithms to guarantee the accuracy of patient-specific QA. Materials and Methods: Ten VMAT plans with 6 MV photon beam and ten VMAT plans with 15 MV photon beam were selected retrospectively. The computed tomography (CT) images of MapCHECK2 with MapPHAN were acquired to design the virtual phantom images. For all plans, dose distributions were calculated for the virtual phantoms with four different materials by AAA and AXB algorithms. The four materials were polystyrene, 455 HU, Jursinic phantom, and PVC. Passing rates for several gamma criteria were calculated by comparing the measured dose distribution with calculated dose distributions of four materials. Results and Discussion: For validation of AXB modeling in clinic, the mean percentages of agreement in the cases of dose difference criteria of 1.0% and 2.0% for 6 MV were $97.2%{\pm}2.3%$, and $99.4%{\pm}1.1%$, respectively while those for 15 MV were $98.5%{\pm}0.85%$ and $99.8%{\pm}0.2%$, respectively. In the case of 2%/2 mm, all mean passing rates were more than 96.0% and 97.2% for 6 MV and 15 MV, respectively, regardless of the virtual phantoms of different materials and dose calculation algorithms. The passing rates in all criteria slightly increased for AXB as well as AAA when using 455 HU rather than polystyrene. Conclusion: The virtual phantom which had a 455 HU values showed high passing rates for all gamma criteria. To guarantee the accuracy of patent-specific VMAT QA, each institution should fine-tune the mass density or HU values of this device.

• The Korean Journal of Physiology and Pharmacology
• /
• 제6권3호
• /
• pp.139-142
• /
• 2002

To examine intracellular signaling of human $S1P_3\;(hS1P_3),$ a sphingosine 1-phosphate (S1P) receptor in plasma membrane, $hS1P_3$ DNA was transfected into RH7777 rat hepatoma cell line, and the inhibition of forskolin-induced cAMP accumulation and activation of MAP kinases by S1P were tested. In $hS1P_3$ transformants, S1P inhibited forskolin-induced activation of adenylyl cyclase activity by about 80% and activated MAP kinases in dose-dependent and pertussis-toxin (PTX) sensitive manners. In oocytes expressing $hS1P_3$ receptor, S1P evoked $Cl^-$ conductance. These data suggested that PTX-sensitive G proteins are involved in $hS1P_3-mediated$ signaling, especially the positive action of S1P in cell proliferation. The potential advantages of rat hepatoma cells for the research of sphingosine 1-phosphate receptor are discussed.

• BMB Reports
• /
• 제29권6호
• /
• pp.489-492
• /
• 1996

A number of anticancer-chemotherapeutic agents induce cell death through the process of apoptosis. Effects of echinomycin, an anticancer agent on cancer progression, were investigated in P388 murine leukemia cells. First, according to the results of cytotoxicity measurement. $IC_{50}$ of echinomycin was 1.12 nM, a relatively lower value than the other examined anticancer agents, mitomycin-C and etoposide Second, the DNA fragmentation assay for echinomycin-treated cells exhibited that echinomycin was able to induce apoptosis in a shorter period of time and with a lower dose than mitomycin-C or etoposide. The data of DNA fragmentation were quite comparable to those of cytotoxicity measurement. Finally we showed that mitogen-activated protein (MAP) kinase, a key protein in cell mitosis, was translocated into the nucleus from the cytosol after treatment with echinomycin. These findings suggest that a MAP kinase-related process may be involved in apoptosis induced by echinomycin.

• Asian-Australasian Journal of Animal Sciences
• /
• 제15권7호
• /
• pp.957-962
• /
• 2002

In July, three trials were conducted to evaluate the best sponge type and optimum PMSG dose to be administered to sheep under the Jordanian Badia (arid) conditions. In trial 1, three flocks (n=77, n=18 and n=47 for flocks 1, 2 and 3, respectively) were administered with 40 mg fluorogestone acetate (FGA) intravaginal sponges for 12 days before receiving 600 IU of PMSG at the time of sponge removal. In trial 2, 95 ewes were assigned to 4 groups to receive 300 (n=25), 450 (n=27), 600 (n=22) or 750 (n=21) IU of PMSG following a 12 d FGA 40 mg sponge insertion period. In trial 3, 60 ewes were assigned to 3 groups (n=20) to receive either FGA 30 mg, FGA 40 mg or medroxyprogesterone acetate (MAP) 60 mg intravaginal sponges all followed by an administration of 600 IU of PMSG at sponge removal. In all trials, rams were isolated 1 day before sponge insertion and were allowed back with the ewes at sponge removal. Estrual responses and lambing data were collected. The effects of treatment, milking status and face color on estrual responses and lambing data were examined. In trial 1, greater first cycle conception rate (p<0.05), twinning rate (p<0.01) and the number of lambs born/served ewe (p<0.01) were observed in flock 2 compared with flocks 1 and 3. Neither face color nor milking status had any influence on the measured parameters (p>0.05). Despite low lambing rate in trial 2, ewes receiving 600 IU of PMSG had greater (p<0.05) number of lambs born/served ewe compared with ewes receiving 450 IU of PMSG. Regardless of PMSG dose, intervals to detected estrus occurred 10 h earlier (p<0.01) in dry than lactating ewes. Similar to trial 2, lambing rate was depressed in trial 3. The expression of estrus was advanced (p<0.05) in ewes receiving MAP 60 mg sponges compared with those receiving FGA 30 and FGA 40 mg sponges (42$\pm$3.1, 49$\pm$3.1 and 49$\pm$3.1 h post sponge removal in ewes receiving MAP 60 mg, FGA 30 mg and FGA 40 mg sponges, respectively). Other parameters were not influenced (p>0.05) by sponge type, milking status and face color. Data show that a 600 IU dose of PMSG tends to give the best lambing results. In addition, results indicate that the use 60 mg MAP sponges for estrus synchronization may be more appropriate under the Jordanian Badia conditions during late seasonal anestrus.

• Asian-Australasian Journal of Animal Sciences
• /
• 제22권6호
• /
• pp.788-795
• /
• 2009

Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis under various physiological and pathological conditions. We found that the VEGF isoforms VEGF120, VEGF164, and VEGF188 were expressed in the bovine mammary gland and bovine mammary epithelial cells (bMECs). Expression of VEGF in the mammary gland was significantly higher during the lactation period than during the dry period. Although dexamethasone or prolactin alone had little effect on the expression of VEGF, that in dexamethasone-treated cells was significantly induced after additional treatment with prolactin. Furthermore, the VEGF expression induced by the combination of dexamethasone and prolactin was reduced by PD98059 in a dose-dependent manner. This combination also stimulated the phosphorylation of p44/p42 MAP kinase in these cells. These results strongly suggest that the combination of dexamethasone and prolactin stimulates VEGF expression in bMECs via p44/p42 MAP kinase.

• Archives of Pharmacal Research
• /
• 제28권11호
• /
• pp.1257-1262
• /
• 2005

MMP-9 is a metalloproteinase capable of basement membrane degradation in vivo. Expression of MMP-9 can be found in normal conditions such as trophoblasts, osteoclasts, and leukocytes and their precursors. They also occur as well as in pathological conditions, such as the invasive growth of primary tumors, metastasis, angiogenesis, rheumatoid arthritis, and periodontal diseases. MMP-9 upregulation can be highly induced by a wide range of agents. These agents include growth factors, cytokines, cell-cell, and cell-ECM adhesion molecules, and agents altering cell shape. Here, we observed that TNF-$\alpha$ stimulated human monocytic cell line, HL-60 produced MMP-9 in a dose and time dependent manner. Real time PCR results indicated transcriptional upregulation of MMP-9 as early as 3 h post TNF-$\alpha$ stimulation. To investigate the signaling pathway underlined in TNF-$\alpha$ induced MMP-9 expression, three MAP kinase inhibitors were added to cells 1 h prior to TNF-$\alpha$ treatment. The ERK inhibitor completely abolished MMP-9 expression by TNF-$\alpha$. But neither p38 MAP kinase nor JNK inhibitor had an effect on TNF-$\alpha$ induced MMP-9 expression, suggesting that ERK activation is required for the MMP-9 induction by TNF-$\alpha$. Taken together, we found that TNF-$\alpha$ stimulation facilitates ERK activation, which results in the transcriptional upregulation of MMP-9 gene and subsequent MMP-9 production and secretion.

• The Korean Journal of Physiology and Pharmacology
• /
• 제17권4호
• /
• pp.339-345
• /
• 2013

We investigated the antihypertensive effect of lutein on $N^G$-nitro-L-arginine methyl ester hydrochloride (L-NAME)-induced hypertensive rats. Daily oral administration of L-NAME (40 mg/kg)-induced a rapid progressive increase in mean arterial pressure (MAP). L-NAME significantly increased MAP from the first week compared to that in the control and reached $193.3{\pm}9.6$ mmHg at the end of treatment. MAP in the lutein groups was dose-dependently lower than that in the L-NAME group. Similar results were observed for systolic and diastolic blood pressure of L-NAME-induced hypertensive rats. The control group showed little change in heart rate for 3 weeks, whereas L-NAME significantly reduced heart rate from $434{\pm}26$ to $376{\pm}33$ beats/min. Lutein (2 mg/kg) significantly prevented the reduced heart rate induced by L-NAME. L-NAME caused hypertrophy of heart and kidney, and increased plasma lipid peroxidation four-fold but significantly reduced plasma nitrite and glutathione concentrations, which were significantly prevented by lutein in a dose-dependent manner. These findings suggest that lutein affords significant antihypertensive and antioxidant effects against L-NAME-induced hypertension in rats.

• 한국의학물리학회지:의학물리
• /
• 제28권4호
• /
• pp.164-170
• /
• 2017

One of the methods to consider the effect of respiratory motion of a tumor target in radiotherapy is to establish a treatment plan with the internal target volume (ITV) created based on an accurate analysis of the target motion displacement. When this method is applied to intensity modulated radiotherapy (IMRT), it is expected to yield a different treatment dose distribution under the motion condition according to the IMRT method. In this study, we prepared ITV-based IMRT plans with conventional IMRT using fixed gantry angle beams, RapidArc using volumetric modulated arc therapy, and tomotherapy using helical therapy. Then, the variation in dose distribution caused by the target motion was analyzed by the dose measurement in the actual motion condition. A delivery quality assurance plan was prepared for the established IMRT plan and the dose distribution in the actual motion condition was measured and analyzed using a two-dimensional diode detector placed on a moving phantom capable of simulating breathing movements. The dose measurement was performed considering only a uniform target shape and motion in the superior-inferior (SI) direction. In this condition, it was confirmed that the error of the dose distribution due to the target motion is minimum in tomotherapy. This is thought to be due to the characteristic of tomotherapy that treats the target sequentially by dividing it into several slices. When the target shape is uniform and the main target motion direction is SI, it is considered that tomotherapy for the ITV-based IMRT method has a characteristic which can reduce the dose difference compared with the plan dose under the target motion condition.